{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:27:11Z","timestamp":1776270431587,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460282"],"award-info":[{"award-number":["82460282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Deutetrabenazine is a widely used drug for the treatment of tardive dyskinesia (TD), and post-marketing testing is important. There is a lack of real-world, large-sample safety studies of deutetrabenazine. In this study, a pharmacovigilance analysis of deutetrabenazine was performed based on the FDA Adverse Event Reporting System (FAERS) database to evaluate its relevant safety signals for clinical reference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse events (AEs) of FAERS with deutetrabenazine as the primary suspect drug were collected from the first quarter (Q1) of 2017 to Q1 of 2024. Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) were used to mine AEs risk signals of deutetrabenazine. AEs were standardized and classified using the System Organ Class (SOC) and Preferred Terms (PTs) from Medical Dictionary for Regulatory Activities (MedDRA) version 23.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,583 AEs with deutetrabenazine as the primary suspect drug were collected in this study. We found that these AEs involved 23 SOCs, and the positive signals were mainly concentrated in systemic disease and various reactions at the site of administration (n = 1816, ROR = 1.23, PRR = 1.18, IC = 0.24, EBGM = 1.18), neurological disorders (n = 1736, ROR = 3.02, PRR = 2.60, IC = 1.38, EBGM = 2.60) and psychiatric disorders (n = 1,659, ROR = 4.15, PRR = 3.52, IC = 1.82, EBGM = 3.52). We eventually identified 100 valid PTs that met the criteria of the four algorithms. Drug ineffective, dyskinesia, depression, somnolence, suicidal ideation were considered to be the common PTs of deutetrabenazine. Tongue thrust (n = 4, ROR 253.47, PRR 253.35, IC 7.88, EBGM 235.95), grunting (n = 5, ROR 78.49, PRR 78.45, IC 6.26, EBGM 76.71) and drooling (n = 17, ROR 13.21, PRR 13.19, IC 3.72, EBGM 13.14) were not mentioned in the specification, but the high signal intensity suggested that they may be the potential adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy of deutetrabenazine may be accompanied by some potential adverse effects in several systems. Adverse events in psychiatric, neurologic, gastrointestinal and respiratory need to be monitored in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1498215","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:38:39Z","timestamp":1734935919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Yanping","family":"Shu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sichao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianlin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101208","DOI":"10.1016\/j.xcrm.2023.101208","article-title":"Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia","volume":"4","author":"Abe","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1016\/j.arr.2022.101832","article-title":"The impact of age on intensive care","volume":"84","author":"Akinosoglou","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiat"},{"key":"B4","volume-title":"Package insert. Teva neuroscience","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J. Neurological Sci. Official Bull. World Fed. Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/JCP.0000000000001229","article-title":"Correlates of the abnormal involuntary movement scale in veterans with tardive dyskinesia","volume":"40","author":"Caroff","year":"","journal-title":"J. Clin. Psychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/JCP.0000000000001201","article-title":"RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings","volume":"40","author":"Caroff","year":"","journal-title":"J. Clin. Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","article-title":"Oxidative stress and tardive dyskinesia: pharmacogenetic evidence","volume":"46","author":"Cho","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40264-023-01355-8","article-title":"Comparative analysis of information provided in German adverse drug reaction reports sent by physicians, pharmacists and consumers","volume":"46","author":"Christ","year":"2023","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.2147\/NDT.S328301","article-title":"Tardive dyskinesia in older persons taking antipsychotics","volume":"17","author":"Citrome","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/1535370221991830","article-title":"Dysregulation of brain dopamine systems in major depressive disorder","volume":"246","author":"Delva","year":"2021","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di-Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. and Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/jnnp-2018-319918","article-title":"Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia","volume":"90","author":"Fernandez","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40120-024-00600-1","article-title":"Safety of deutetrabenazine for the treatment of tardive dyskinesia and chorea associated with huntington disease","volume":"13","author":"Frank","year":"2024","journal-title":"Neurol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0165-0327(93)90051-K","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5334\/tohm.842","article-title":"Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review","volume":"14","author":"Golsorkhi","year":"2024","journal-title":"Tremor Other Hyperkinet Mov. (N Y)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12035-009-8059-y","article-title":"Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons","volume":"39","author":"Guillot","year":"2009","journal-title":"Mol. Neurobiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.isci.2020.101240","article-title":"Ablation of ventral Midbrain\/Pons GABA neurons induces mania-like behaviors with altered sleep homeostasis and dopamine D(2)R-mediated sleep reduction","volume":"23","author":"Honda","year":"2020","journal-title":"iScience"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00228-024-03722-5","article-title":"Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis","volume":"80","author":"Ismail","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B28","first-page":"37","article-title":"Extracting and standardizing medication information in clinical text \u2013 the MedEx-UIMA system","volume":"2014","author":"Jiang","year":"2014","journal-title":"Amia Summits Transl. Sci. Proc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1021\/acschemneuro.4c00152","article-title":"The importance of stereochemistry in 5-ht7r Modulation\u2500A case study of hydantoin derivatives","volume":"15","author":"Kucwaj-Brysz","year":"2024","journal-title":"Acs Chem. Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1177\/02698811231200881","article-title":"Dopamine in major depressive disorder: a systematic review and meta-analysis of in vivo imaging studies","volume":"37","author":"Mizuno","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/phar.2325","article-title":"Impact of a new consumer form on the quantity and quality of adverse event reports submitted to the United States food and drug administration","volume":"39","author":"Munoz","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1017\/S0033291722001222","article-title":"Multi-modal assessment of reward functioning in adolescent anhedonia","volume":"53","author":"Murray","year":"2023","journal-title":"Psychol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-019-1385-4","article-title":"Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis","volume":"19","author":"Patterson-Lomba","year":"2019","journal-title":"BMC Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Rev. Can. Psychiatr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/pds.3687","article-title":"Adverse drug reaction reports of patients and healthcare professionals-differences in reported information","volume":"24","author":"Rolfes","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jagp.2021.08.003","article-title":"Long-Term safety and efficacy of deutetrabenazine in younger and older patients with tardive dyskinesia","volume":"30","author":"Sajatovic","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"TV18059BR1C","DOI":"10.4088\/JCP.TV18059BR1C","article-title":"Identifying tardive dyskinesia: risk factors, functional impact, and diagnostic tools","volume":"81","author":"Saklad","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndromes","volume":"389","author":"Savitt","year":"2018","journal-title":"J. Neurological Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","author":"Schultz","year":"2018","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. neurological Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S1092852918001219","article-title":"Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1017\/S1092852917000542","article-title":"Tardive dyskinesia: motor system impairments, cognition and everyday functioning","volume":"23","author":"Strassnig","year":"2018","journal-title":"CNS spectrums"},{"key":"B46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ggi.13669","article-title":"Tardive dyskinesia after drug withdrawal in two older adults: clinical features, complications and management","volume":"19","author":"Thomson","year":"2019","journal-title":"Geriatrics and Gerontology Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"R585","DOI":"10.1152\/ajpregu.00455.2014","article-title":"Dopamine, vesicular transporters, and dopamine receptor expression in rat major salivary glands","volume":"309","author":"Tomassoni","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40263-024-01078-z","article-title":"An Evidence-Based update on anticholinergic use for Drug-Induced movement disorders","volume":"38","author":"Vanegas-Arroyave","year":"2024","journal-title":"Cns Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"110289","DOI":"10.1016\/j.pnpbp.2021.110289","article-title":"Anhedonia as a central factor in depression: neural mechanisms revealed from preclinical to clinical evidence","volume":"30","author":"Wang","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.genhosppsych.2024.06.005","article-title":"Mining of neurological adverse events associated with valbenazine: a post-marketing analysis based on FDA adverse event reporting system","volume":"90","author":"Zhang","year":"2024","journal-title":"Gen. Hosp. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1498215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:38:41Z","timestamp":1734935921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1498215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":52,"alternative-id":["10.3389\/fphar.2024.1498215"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1498215","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1498215"}}